Lee Schwartzberg, MD, FACP, executive director, West Cancer Center, discusses how patients are responding to using biosimilars.
Most patients are not necessarily aware of biosimilars yet. It's still very new. It's still new for the practitioners. When it's explained in a fashion that they can understand, they've been overwhelmingly enthusiastic and supportive about it.